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ABSTRACT
Objectives: Peroxiredoxins (PRDXs) constitute a family of antioxidant enzymes which are also involved in the process of 
carcinogenesis. They are composed of six identified isoforms (PRDX-1-6) and are supposed to play different roles in tumor 
progression, depending on type of cancer and member of the PRDX family. The aim of the study was to assess the prog-
nostic value of PRDXs in ovarian cancer.
Material and methods: a dataset of patients with ovarian cancer from The Cancer Genome Atlas was analyzed. Expression 
of PRDX-1 to 6 mRNA was evaluated in 260 samples. The prognostic value of PRDXs was assessed using the Cox regression 
model which included the following clinical and pathological data: age, clinical stage, tumor grade, and residual disease.
Results: Within the PRDXs family, only higher expression of PRDX-5 was associated with worse overall survival both, in 
unselected patients and >50-year-olds. PRDX-5 expression and residual disease were independent negative prognostic 
factors of patient survival.
Conclusions: PRDX-5 is a negative predictor of survival in ovarian cancer.
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 INTRODUCTION
Ovarian cancer (OC) remains the leading cause of 
cancer-related deaths among females in the developed 
countries [1]. High mortality rate is the consequence of late 
diagnosis, which in turn is the result of relatively oligosymp-
tomatic course of early-stage OC and lack of screening tests 
which could be used in low-risk populations [2]. Despite 
significant progress in the management of ovarian cancer, 
the overall 5-year survival for all stages of the disease is 
about 30% [3]. Little is known about the predictive fac-
tors which would indicate a specific and more effective 
strategy of treatment. Cisplatin and Poly-(ADP-ribose)-pol-
ymerase1 (PARP1) administration in BRCA-mutated patients 
is one of the exceptions [4]. Resistance to chemotherapy is 
another major problem in a successful OC treatment. Over-
coming primary or secondary resistance to chemotherapy 
requires a multidirectional strategy, which includes better 
knowledge of the biomarkers for survival prediction and are 
supposed to be involved in the development of resistance 
to chemotherapeutic agents.
Peroxiredoxins (PRDXs) are a ubiquitous family of an-
tioxidant enzymes which also control cytokine-induced 
peroxide levels which mediate signal transduction in mam-
malian cells [5]. They are composed of six identified isoforms: 
PRDX1, PRDX2, PRDX3, PRDX4, PRDX5, and PRDX6 [6]. Under 
physiological conditions, they are responsible for protect-
ing cells against oxidative DNA damage and genomic in-
stability, regulating cell signaling associated with H2O2, 
influencing cell differentiation and proliferation, immune 
responses and apoptosis [7]. In vitro and in vivo studies have 
demonstrated that the overexpression of PRDXs may either 
inhibit cancer development or promote cancer growth, 
depending on the specific PRDX family member and the 
cancer context [8]. PRDX-1 and PRDX-2 are the two repre-
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sentatives of the PRDX family which have a dual effect in 
carcinogenesis. PRDX-1 is overexpressed in lung, bladder 
and ovarian cancers, in aggressive esophageal squamous 
carcinomas, hilar cholangiocarcinoma, liver and pancre-
atic cancer, in mesothelioma and in glioblastoma, whereas 
high levels of PRDX-2 were observed in ovarian borderline 
tumors, colorectal cancers, vaginal, cervical, prostate and 
esophageal cancers and B-cell-derived primary lymphoma 
cells, suggesting their role in tumor progression [7]. How-
ever, biomarker studies demonstrated that PRDX-1 protects 
estrogen receptors (ERα) from the oxidative stress‐induced 
suppression and is a protein marker of favorable prognosis in 
mammary tumors [9]. A decreased expression of PRDX-2 has 
been demonstrated in only a few types of cancer, including 
the melanomas, where the downregulation of PRDX-2 cor-
related with increased proliferative and migratory activities, 
and with the acquisition of a metastatic potential of the 
tumor [10]. The studies on PRDX-3 have demonstrated that 
its overexpression in hepatocellular, lung, breast, prostate 
and cervical cancers correlates with a more aggressive phe-
notype [11–15]. PRDX-4 enhances the rate of cell prolifera-
tion in prostate cancer and increases metastatic potential in 
oral cavity squamous cell, breast, lung and ovarian cancers 
[16–19]. Overexpression of PRDX-5 has been found in ag-
gressive Hodgkin’s lymphomas, malignant mesothelioma, 
breast, ovarian and thyroid cancer [20–24]. Increased levels 
of PRDX-6 have been associated with a more invasive phe-
notype and metastatic potential of breast cancer, and with 
a worse prognosis of clinically localized prostate cancer 
following radical prostatectomy [25, 26]. Finally, high levels 
of PRDX-1, 2, 3 and 6 correspond to resistance to cisplatin 
in several cancers [7]. The undisputable role of PRDXs in 
tumorigenicity makes these proteins candidates for mark-
ers of prognosis. Possibly, in the future research on such 
novel biomarkers may help identify patients who require 
specific, personalized approach, which could be another 
step towards improving the OC outcomes.
Objectives
The aim of our study was to investigate the prognostic 
significance of the PRDX family overexpression at the mRNA 
level in patients with ovarian cancer.
MATERIAL AND METHODS
The ovarian cancer normalized Agilent G4502A data 
(level 3) was acquired from The Cancer Genome Atlas 
(TCGA) (https://www.nature.com/articles/nature10166). TCGA 
is a collaboration between the National Cancer Institute 
(NCI) and the National Human Genome Research Institute 
(NHGRI), which generated multi-dimensional maps of the 
key genomic changes in 33 types of cancer with poor prog-
nosis. The dataset is publicly available and includes sam-
ples from patients with ovarian cancers. In this study, we 
analyzed the expression of PRDX-1 to 6 mRNA in patients 
with ovarian cancer. A total of 270 subjects were included in 
the study. In order to run a multivariable Cox proportional 
hazard model for the overall survival, the following ad-
ditional independent variables were included: age, clinical 
stage, tumor grade, and residual disease. A subgroup of 
215 patients > 50 years of age was selected from the study 
population to focus our study on the late-onset patients. The 
patients were further stratified into groups according to 
the quantiles of PRDX mRNA levels defining the follow-
ing thresholds: Q1 – lower quartile, Q2 median, Q3 upper 
quartile. Characteristics of the entire study population and 
the group of  > 50-year-olds are presented in Tables 1 and 2. 
Kaplan–Meier plots were generated to visualize the dif-
ferences in the overall survival between selected subgroups 
of the investigated OC patients. Differences in the survival 
were statistically compared using the Cox proportional 
hazard regression model to simultaneously assess the ef-
fect of additional risk factors on the survival. The p-value 
of < 0.05 was considered as statistically significant. All 
analyses were performed using R. Local Ethics Committee 
approved of the study.
Table 1. Characteristics of the entire study population. Values 
present mean ± SD or the number of cases (%). Cox regression 
P-value. Q-quartile
Q1 (N = 68) Q2-4 (n = 202) P
Age (mean ± SD)
PRDX1
PRDX2
PRDX3
PRDX4
PRDX5
PRDX6
60.47 ± 11.14
60.02 ± 11.51
60.81 ± 11.51
59.53 ± 11.31
59.98 ± 11.08
60.08 ± 11.16
61.01 ± 12.37
62.34 ± 11.13
60.00 ± 11.28
63.79 ± 11.31
62.47 ± 12.34
62.15 ± 12.19
0.267
0.246
0.271
0.409
0.499
0.269
Stage (I-II vs. III-IV), N (%)
PRDX1
PRDX2
PRDX3
PRDX4
PRDX5
PRDX6
13 (19.4%)
10 (14.7%)
15 (22.1%)
12 (17.6%)
12 (17.6%)
8 (11.9%)
40 (19.8%)
43 (21.4%)
38 (18.9%)
41 (20.4%)
41 (20.4%)
45 (22.3%)
0.903
0.917
0.898
0.915
0.862
0.892
Grade (G1-2 vs. G3), N (%)
PRDX1
PRDX2
PRDX3
PRDX4
PRDX5
PRDX6
53 (79.1%)
61 (91.0%)
59 (89.4%)
57 (87.7%)
61 (92.4%)
60 (89.6%)
175 (89.7%)
167 (85.6%)
169 (86.2%)
171 (86.8%)
167 (85.2%)
168 (86.2%)
0.128
0.144
0.135
0.125
0.110
0.135
Residual volume (absent vs. present), N (%)
PRDX1
PRDX2
PRDX3
PRDX4
PRDX5
PRDX6
42 (73.7%)
45 (76.3%)
47 (78.3%)
42 (72.4%)
43 (72.9%)
46 (76.7%)
131 (73.6%)
128 (72.7%)
126 (72.0%)
131 (74.0%)
130 (73.9%)
127 (72.6%)
0.011
0.021
0.012
0.009
0.010
0.012
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RESULTS 
The overall survival multivariate analysis revealed that 
higher expression of PRDX-5 was independently associated 
with worse overall survival within the first five years after 
the initial diagnosis. The difference was observed in the 
entire study population for the Q1 threshold (within the 1st 
quartile) (P < 0.05) (Fig. 1), and in the group of > 50-year-olds 
for the Q2 threshold (within the median) (P < 0.04) (Fig. 2). 
Median overall survival was 1364 (95%CI 1162–1652) days 
vs. 1919 (95%CI 1418-NA) days in the entire group and 
1364 (95%CI 1184–1882) days vs. 1919 (95%CI 1684–2780) 
days in the group of > 50-year-olds. No differences in the 
survival between the groups with different expression of 
PRDX-1, 2, 3, 4 and 6 were found. The results also revealed 
a significant influence of the residual disease on the re-
duced overall survival in the investigated cases (P = 0.01 and 
P = 0.013, in all patients and > 50-year-olds, respectively). 
In contrast, the clinical stage, tumor grade and age did not 
indicate significant effects on the overall survival.
DISCUSSION
PRDXs play a critical role in several physiological and 
pathological conditions involving redox signaling. Although 
their role in some benign conditions has been well under-
stood, the influence of PRDXs on carcinogenesis remains 
controversial [8, 27]. Different PRDX isoforms may have 
a tumorsuppressor or an oncogenic role, depending on 
the cancer type [7]. Thus, it is impossible to create a univer-
sal description of PRDXs as prognostic factors in mamma-
lian malignant tumors. Regardless of the fact that several 
studies of PRDXs in various cancers have been published, 
little is known about their impact on the prognosis in OC pa-
tients. In the present study, we investigated the role of all six 
members of the PRDX family as markers of prognosis in ovar-
ian cancer. According to our results, a higher expression of 
PRDX-5 is associated with poorer overall survival both, in all 
ovarian cancer patients and in the group of > 50-year-olds. 
Our findings support the claims presented in other stud-
ies that PRDX-5 may give tumor-promoting effects in mam-
malian cancers. On the molecular level, transcription factors 
such as AP1, nuclear factorκB (NFκB), antioxidant response 
element, insulin response element, glucocorticoid response 
element, and also cMyc may directly modulate the expression 
of PRDX5 [28, 29]. CMyc also contributes to the maintenance 
of reactive oxygen species homeostasis through its ability 
to selectively induce the transcription of specific PRDXs 
when the function of one of them is compromised [29]. 
In clinical studies, the overexpression of PRDX-5 was signifi-
cantly associated with tumor size and depth, and lymphatic 
invasion in gastric cancer, which in turn contributed to poor 
prognosis [30]. In our study, besides PRDX-5, residual disease 
but not age, clinical stage and tumor grade was an inde-
pendent marker of poor prognosis. Byun et al., found that 
high expression of PRDX-5 was more frequently observed 
in advanced-stage endometrial cancer and tended to be 
associated with the presence of lymph node metastases 
but that the 5-year survival rate did not significantly dif-
fer depending on the PRDX-5 expression [31]. Similarly, 
in the study of Karihtala et al., an elevated cytoplasmic ex-
pression of PRDX-5 was associated with a higher stage of 
ovarian cancer but no analysis of survival was conducted [32]. 
Notably, in our study PRDX-5 expression was a nega-
tive prognostic indicator of survival both, in the entire 
study population and in the subgroup of > 50-year-olds. 
However, further studies are needed as this finding may start 
the debate on different roles of PRDXs in hereditary and 
sporadic ovarian cancers since the population of patients 
aged > 50 comprises fewer cases of hereditary ovarian can-
cer as compared to the younger group [33]. 
To the best of our knowledge, there has been only one 
study in patients with adrenocortical carcinoma which pre-
sented distinct results [34]. PRDX-5 expressed by cDNA mi-
croarray was 2.5-fold downregulated in adrenocortical car-
cinoma compared to benign adrenocortical tumors. These 
findings encouraged the authors to call PRX-5 a candidate 
Table 2. Characteristics of the group of  > 50-year-olds. Values 
present mean ± SD or the number of cases (%). Cox regression 
P-value. Q-quartile
Q1-2 (N = 108) Q3-4 (n = 107) P
Age (mean ± SD)
PRDX1
PRDX2
PRDX3
PRDX4
PRDX5
PRDX6
64.30 ± 9.18
64.08 ± 8.74
64.54 ± 8.85
63.04 ± 8.84
63.42 ± 8.55
64.92 ± 9.23
65.24 ± 8.77
65.46 ± 9.18
65.00 ± 9.12
66.50 ± 8.80
66.12 ± 9.21
64.62 ± 8.73
0.674
0.573
0.745
0.742
0.848
0.630
Stage (I-II vs. III-IV), N (%)
PRDX1
PRDX2
PRDX3
PRDX4
PRDX5
PRDX6
14 (13.3%)
13 (12.3%)
14 (13.2%)
16 (15.1%)
19 (17.9%)
12 (11.4%)
22 (20.8%)
23 (21.9%)
22 (21.0%)
20 (19.0%)
17 (16.2%)
24 (22.6%)
0.443
0.491
0.470
0.525
0.652
0.488
Grade (G1-2 vs. G3), N (%)
PRDX1
PRDX2
PRDX3
PRDX4
PRDX5
PRDX6
87 (84.5%)
92 (89.3%)
90 (86.5%)
92 (88.5%)
96 (93.2%)
93 (90.3%)
92 (90.2%)
87 (85.3%)
89 (88.1%)
87 (86.1%)
83 (81.4%)
86 (84.3%)
0.292
0.280
0.255
0.244
0.137
0.262
Residual volume (absent vs. present), N (%)
PRDX1
PRDX2
PRDX3
PRDX4
PRDX5
PRDX6
67 (73.6%)
71 (78.0%)
71 (75.5%)
66 (72.5%)
68 (76.4%)
70 (75.3%)
69 (74.2%)
65 (69.9%)
65 (72.2%)
70 (75.3%)
68 (71.6%)
66 (72.5%)
0.011
0.005
0.009
0.008
0.013
0.008
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Figure 1. Kaplan-Meier analysis of the overall survival probability in all patients split based on the Q1 (1st quartile) threshold of PRDX 1-6 mRNA. Cox 
proportional hazard model regression was used to compute the significance of the clinical variables as well as the respective PRDX mRNA levels
Figure 2. Kaplan-Meier analysis of the overall survival probability in patients over 50 y/o split based on the Q2 (median) threshold of PRDX 1-6 mRNA. 
Cox proportional hazard model regression was used to compute the significance of the clinical variables as well as the respective PRDX mRNA levels
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for the tumor suppressor gene and a diagnostic marker for 
distinguishing adrenocortical carcinoma from adenoma. 
However, no data on survival were available.
In this study, we found no association between PRDX- 
1, 2, 3, 4 and 6 expression and patient survival. The number 
of studies investigating the association of PRDXs expression 
and survival in ovarian cancer is limited. Chung et al., com-
pared PRDX-1 expression between serous borderline tumors 
and serous carcinoma and observed that PRDX-1 was over-
expressed in most malignant ovarian tumors and correlated 
with poor overall survival in patients with ovarian serous 
carcinoma [35]. A study of Karihtala et al., evaluating 68 in-
vasive ovarian carcinomas using immunohistochemistry 
reported that high cytoplasmic PRDX-4 immunostaining 
was associated with better prognosis [32].
Other reports showed an overexpression of PRDXs in OC 
tumors but the conclusions about the role of PRDXs in tumor 
progression are usually inconclusive or inconsistent. Li et al., 
based their opinion about the suppressive role of PRDX-2 in 
ovarian cancer progression only on its decreased expression 
in cancerous tissues compared with normal ovary [36]. The 
studies of PRDX-3 identified the subgroups of patients with 
a higher expression of this protein (poorly-differentiated, 
higher clinical stage) but found no relationship with OS or 
PFS [37, 38]. In the abovementioned study of Karihtala et 
al., an elevated cytoplasmic expression rate of PRDX-6 was 
associated with a higher stage of OC but no prognostic 
value of that protein was found [32]. To sum up, the avail-
able studies have demonstrated that PRDX-s overexpression 
is commonly observed in ovarian cancer, but the clinical 
significance of these findings remains to be elucidated.
Our study was not without limitations, chief among 
them the fact that the analysis was conducted on the mRNA 
level. We realize that the results should be repeated on the 
protein level. However, the dataset, although medium size, is 
relatively homogenic as it comes from one database, which 
strengthens the evidence. 
CONCLUSIONS
PRDX-5 is a negative marker of survival in ovarian cancer 
patients and further studies are necessary to learn more 
about the specific role of PRDX-5 in ovarian cancer. 
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